-
Product Insights
NewP2Y Purinoceptor 12 – Drugs In Development, 2024
The P2Y Purinoceptor 12 pipeline drugs market research report outlays comprehensive information on the P2Y Purinoceptor 12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, and Central Nervous System which include indications of Myocardial Infarction, Acute Coronary Syndrome, Neuropathic Pain (Neuralgia), and Inflammatory Pain. It also reviews key players involved in P2Y Purinoceptor 12 targeted therapeutics...
-
Product Insights
NewInterleukin 12 Receptor – Drugs In Development, 2024
The Interleukin 12 Receptor pipeline drugs market research report outlays comprehensive information on the Interleukin 12 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Hematological Disorders, and Toxicology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Plaque Psoriasis (Psoriasis Vulgaris), Leukocyte Disorders (White Blood Cell Disorders), Thrombocytopenia, and Chemotherapy Effects....
-
Product Insights
NewCyclin Dependent Kinase 12 – Drugs In Development, 2024
The Cyclin Dependent Kinase 12 pipeline drugs market research report outlays comprehensive information on the Cyclin Dependent Kinase 12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Breast Cancer, and Ovarian Cancer. It also reviews key players involved in Cyclin Dependent Kinase 12 targeted therapeutics development with respective active and dormant or...
-
Product Insights
NewInterleukin 12 Subunit Beta – Drugs In Development, 2024
The Interleukin 12 Subunit Beta pipeline drugs market research report outlays comprehensive information on the Interleukin 12 Subunit Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Gastrointestinal, Musculoskeletal Disorders, and Oncology which include indications of Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Psoriatic Arthritis, Axial Spondyloarthritis, Ovarian Cancer, and Prostate Cancer....
-
Product Insights
NewSolute Carrier Family 22 Member 12 – Drugs In Development, 2024
The Solute Carrier Family 22 Member 12 pipeline drugs market research report outlays comprehensive information on the Solute Carrier Family 22 Member 12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Musculoskeletal Disorders, Metabolic Disorders, Genito Urinary System, and Gastrointestinal which include indications of Gouty Arthritis (Gout), Hyperuricemia, Chronic Kidney Disease (Chronic Renal Failure), Metabolic Dysfunction-Associated Steatohepatitis...
-
Product Insights
NewSolute Carrier Family 12 Member 2 – Drugs In Development, 2024
The Solute Carrier Family 12 Member 2 pipeline drugs market research report outlays comprehensive information on the Solute Carrier Family 12 Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genetic Disorders, and Cardiovascular which include indications of Autism Spectrum Disorder (ASD), Epilepsy, Down Syndrome, Fragile X Syndrome, and Ischemic Stroke. It also...
-
Product Insights
NewSolute Carrier Family 12 Member 3 – Drugs In Development, 2024
The Solute Carrier Family 12 Member 3 pipeline drugs market research report outlays comprehensive information on the Solute Carrier Family 12 Member 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular which include indications of Idiopathic (Essential) Hypertension, and Hypertension. It also reviews key players involved in Solute Carrier Family 12 Member 3 targeted therapeutics development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ROSE-12 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ROSE-12 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ROSE-12 in Solid Tumor Drug Details: ROSE12 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBX-12 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBX-12 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBX-12 in Solid Tumor Drug Details: CBX-12 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBX-12 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBX-12 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBX-12 in Ovarian Cancer Drug Details: CBX-12 is under development for...